Todd Zion | Akston
In This Episode
In this episode of the Veterinary Innovation Podcast, Shawn Wilkie and Dr. Ivan Zak are joined by Todd Zion, Ph.D., the President and CEO of Akston. A chemical engineer by training, Todd previously led the development of the first-ever clinically tested glucose-responsive insulin with his first company, SmartCells, which was acquired by Merck. Now, he’s applying over two decades of experience in protein engineering and drug delivery to solve some of the toughest compliance and cost challenges in veterinary medicine.
Todd discusses Akston’s strategic pivot from human to animal health, focusing on the development of long-acting protein therapeutics. He explains how Akston’s proprietary Ambifect platform is creating innovative, once-every-six-month dosing for conditions like cancer, chronic pain, and dermatitis. This new class of biologics aims to be longer-lasting, easier to manufacture, and more cost-effective than current monthly treatments, providing a vital solution to the rising cost of care and the stress of frequent medication for pet parents. Whether you’re interested in the business side of biotech, the future of chronic disease management, or the regulatory differences between human and veterinary pharma, this conversation offers a compelling look at the next wave of innovation designed for both the pet and their busy owners.
Learn more about Akston.
Todd recommends “Zoobiquity: The Astonishing Connection Between Human and Animal Health” by Barbara Natterson-Horowitz, Kathryn Bowers.
Topics Covered:
- Axten’s Biotechnology Platform and Products
- Veterinary Regulatory and Development Insights
- Biotech Business Strategy